IP Verse

Crf1 Receptor Antagonists For The Treatment Of Congenital Adrenal Hyperplasia - EP3096756

The patent EP3096756 was granted to Neurocrine Biosciences on Jun 12, 2024. The application was originally filed on Jan 21, 2015 under application number EP15702917A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3096756

NEUROCRINE BIOSCIENCES
Application Number
EP15702917A
Filing Date
Jan 21, 2015
Status
Granted And Under Opposition
May 10, 2024
Publication Date
Jun 12, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBMar 7, 2025KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6531475
DESCRIPTIONUS6586456
DESCRIPTIONUS6610678
DESCRIPTIONUS6664261
DESCRIPTIONUS6806282
DESCRIPTIONWO0059888
DESCRIPTIONWO2006044821
DESCRIPTIONWO2006044958
DESCRIPTIONWO2006102194
DESCRIPTIONWO2006107784
DESCRIPTIONWO2006116412
DESCRIPTIONWO2006126718
DESCRIPTIONWO2007069565
DESCRIPTIONWO2007069671
DESCRIPTIONWO2008036541
DESCRIPTIONWO2008036579
DESCRIPTIONWO2008051533
DESCRIPTIONWO2008082003
DESCRIPTIONWO2008083070
DESCRIPTIONWO2008136377
DESCRIPTIONWO2009008552
DESCRIPTIONWO2009144632
DESCRIPTIONWO2010014280
DESCRIPTIONWO2010014687
DESCRIPTIONWO2010015628
DESCRIPTIONWO2010015655
DESCRIPTIONWO2010062718
DESCRIPTIONWO2010096426
DESCRIPTIONWO2011043381
DESCRIPTIONWO2011043387
DESCRIPTIONWO2011092290
DESCRIPTIONWO2011092293
DESCRIPTIONWO2011095450
DESCRIPTIONWO9808846
DESCRIPTIONWO9811075
DESCRIPTIONWO9910350
INTERNATIONAL-SEARCH-REPORTUS8030304

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Ayala Alejandro R, "Behavioral, Adrenal, and Sympathetic Responses to Long-Term Administration of an Oral Corticotropin-Releasing Hormone Receptor Antagonist in a Primate Stress Paradigm", The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 11, (20041101), pages 5729 - 5737, URL: https://academic.oup.com/jcem/article-pdf/89/11/5729/10775159/jcem5729.pdf, XP055933155
EXAMINATION- Künzel Heike E ET AL, "Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects", JOURNAL OF PSYCHIATRIC RESEARCH, GB, (20031101), vol. 37, no. 6, doi:10.1016/S0022-3956(03)00070-0, ISSN 0022-3956, pages 525 - 533, XP055933153
EXAMINATION- B. A. Fleck ET AL, "Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor", Journal of Pharmacology and Experimental Therapeutics, (20120222), vol. 341, no. 2, doi:10.1124/jpet.111.188714, pages 518 - 531, XP055487900
EXAMINATION- ANDREW DAUBER ET AL, "Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia", INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY, BIOMED CENTRAL LTD, LONDON, UK, (20100801), vol. 2010, no. 1, doi:10.1186/1687-9856-2010-347636, ISSN 1687-9856, page 347636, XP021109247
EXAMINATION- HENRIK OSTER ET AL, "The functional and clinical significance of the 24-h rhythm of circulating glucocorticoids", ENDOCRINE REVIEWS, US, (20161017), doi:10.1210/er.2015-1080, ISSN 0163-769X, XP055709793
OPPOSITION- Anonymous, "2-Thiazolamine, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2- cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-2-propyn-1-yl-, hydrochloride (1:1) ", Registry, (20010215), Database accession no. RN 321839-75-2, XP093303788
OPPOSITION- Anonymous, "FDA Approves New Treatment for Congenital Adrenal Hyperplasia", FDA News release, FDA, pages 1 - 2, FDA News release, URL: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-congenital-adrenal-hyperplasia, XP093303785
OPPOSITION- Zorrilla, E.P. ; Koob, G.F., "Progress in corticotropin-releasing factor-1 antagonist development", Drug Discovery Today, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100501), vol. 15, no. 9-10, ISSN 1359-6446, pages 371 - 383, XP027038500
OPPOSITION- Peter Michael, "Congenital Adrenal Hyperplasia: 11β-Hydroxylase Deficiency", Seminars in Reproductive Medicine, (20020101), doi:10.1055/s-2002-35389, pages 1 - 1, XP093266068
OPPOSITION- B. A. Fleck, S. R. J. Hoare, R. R. Pick, M. J. Bradbury, D. E. Grigoriadis, "Binding Kinetics Redefine the Antagonist Pharmacology of the Corticotropin-Releasing Factor Type 1 Receptor", Journal of Pharmacology and Experimental Therapeutics, (20120501), vol. 341, no. 2, doi:10.1124/jpet.111.188714, pages 518 - 531, XP055487900
OPPOSITION- Gully D; Geslin M; Serva L; Fontaine E; Roger P; Lair C; Darre V; Marcy C; Rouby P -E; Simiand J; Guitard J; Gout G; Steinberg R; Rodier D; Griebel G; Soubrie P; Pascal M; Pruss R; Scatton B; Maffrand J -P; Le Fur G, "4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine Hydrochloride (SSR125543A): A Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. I. Biochemical and Pharmacological Characterization", The Journal of Pharmacology and Experimental Therapeutics, Elsevier Inc, United States, United States, (20020401), vol. 301, no. 1, doi:10.1124/jpet.301.1.322, ISSN 0022-3565, pages 322 - 332, XP009524774
OPPOSITION- Guy Griebel , Jacques Simiand , Régis Steinberg , Mireille Jung , Danielle Gully , Pierre Roger , Michel Geslin , Bernard Scatton , Jean-Pierre Maffrand , Philippe Soubrié, "4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1 S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotrophin-Releasing Factor1 Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders", The Journal of Pharmacology and Experimental Therapeutics, Elsevier Inc, United States, United States, (20020401), vol. 301, no. 1, doi:10.1124/jpet.301.1.333, ISSN 0022-3565, pages 333 - 345, XP009562408
OPPOSITION- Andrew Dauber;HenryA Feldman;JosephA Majzoub, "Nocturnal Dexamethasone versus Hydrocortisone for the Treatment of Children with Congenital Adrenal Hyperplasia", International Journal of Pediatric Endocrinology, London, UK , (20100801), vol. 2010, no. 1, doi:10.1186/1687-9856-2010-347636, ISSN 1687-9856, pages 1 - 8, XP021109247
OPPOSITION- KarenJ Loechner;JamesT McLaughlin;AliS Calikoglu, "Alternative Strategies for the Treatment of Classical Congenital Adrenal Hyperplasia: Pitfalls and Promises", International Journal of Pediatric Endocrinology, London, UK , (20100608), vol. 2010, no. 1, doi:10.1186/1687-9856-2010-670960, ISSN 1687-9856, pages 1 - 10, XP021109266
OPPOSITION- E Zoumakis, D K Grammatopoulos, G P Chrousos, "Corticotropin-releasing hormone receptor antagonists", European Journal of Endocrinology, GB , (20061101), vol. 155, no. suppl_1, doi:10.1530/eje.1.02259, ISSN 0804-4643, pages S85 - S91, XP055504816

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents